<DOC>
	<DOC>NCT00764881</DOC>
	<brief_summary>The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year will express the same level of sexual distress when taking SH T00658ID compared to Microgynon, the usual OC prescribed for women with OC-associated FSD.</brief_summary>
	<brief_title>Effects of SH T00658ID on Libido</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>OCassociated female sexual dysfunction (FSD) for at least 3 months but no longer than one year and willingness to continue OC use but to switch to SH T00658ID or Microgynon Combined score of the sexual desire and arousal domains of the FSFI questionnaire of 18 or below at screening and baseline Contraindications for oral contraceptive use, for example but not limited to: presence or history of venous or arterial thrombotic / thromboembolic events, hypertension, presence or history of severe hepatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Oral contraceptive</keyword>
	<keyword>Sexual dysfunction</keyword>
	<keyword>Libido</keyword>
</DOC>